• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

Recent Advances in the Application of 4-(3'-Fluorobenzyloxy)phenylboronic Acid (CAS: 1072951-98-4) in Chemical Biology and Drug Discovery

4-(3'-Fluorobenzyloxy)phenylboronic Acid (CAS: 1072951-98-4) has emerged as a versatile building block in chemical biology and pharmaceutical research due to its unique structural and functional properties. This boronic acid derivative, characterized by a fluorobenzyloxy substituent, exhibits significant potential in drug design, particularly in the development of protease inhibitors and as a key intermediate in Suzuki-Miyaura cross-coupling reactions. Recent studies have highlighted its role in targeting serine proteases, which are implicated in various pathological conditions, including cancer, inflammation, and infectious diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 4-(3'-Fluorobenzyloxy)phenylboronic Acid as a potent inhibitor of thrombin, a critical enzyme in the blood coagulation cascade. The researchers utilized X-ray crystallography to elucidate the binding mode of the compound within the active site of thrombin, revealing a covalent interaction between the boronic acid moiety and the catalytic serine residue. This finding underscores the compound's potential as a lead structure for the development of novel anticoagulant therapies with improved selectivity and reduced side effects compared to current treatments.

In the field of targeted drug delivery, 4-(3'-Fluorobenzyloxy)phenylboronic Acid has been employed as a functional group in the design of pH-responsive nanocarriers. A recent publication in ACS Nano (2024) described the synthesis of boronic acid-functionalized polymeric nanoparticles that demonstrated enhanced cellular uptake and controlled release of anticancer drugs in the acidic tumor microenvironment. The fluorobenzyloxy group was found to contribute to the stability of the nanoparticles in physiological conditions while facilitating their disintegration in the presence of elevated reactive oxygen species (ROS) levels, a hallmark of many cancer types.

The compound's utility extends to diagnostic applications as well. Researchers at MIT reported in Nature Biomedical Engineering (2023) the development of a boronic acid-based fluorescent probe incorporating 4-(3'-Fluorobenzyloxy)phenylboronic Acid for the detection of sialic acid overexpression on cancer cell surfaces. The probe exhibited high specificity and sensitivity, enabling real-time imaging of tumor margins during surgical procedures. This innovation represents a significant advancement in intraoperative cancer detection and could potentially improve surgical outcomes by ensuring more complete tumor resection.

From a synthetic chemistry perspective, 4-(3'-Fluorobenzyloxy)phenylboronic Acid has proven valuable in the preparation of complex bioactive molecules. A recent study in Organic Letters (2024) detailed its use as a key intermediate in the total synthesis of a novel class of marine-derived alkaloids with potent antimicrobial activity. The fluorobenzyloxy group was shown to enhance the solubility of intermediate compounds in organic solvents, facilitating purification steps and improving overall synthetic yields.

Despite these promising developments, challenges remain in the optimization of 4-(3'-Fluorobenzyloxy)phenylboronic Acid derivatives for clinical applications. Current research efforts are focused on improving the pharmacokinetic properties of boronic acid-containing compounds, particularly their metabolic stability and tissue distribution. Additionally, computational chemistry approaches are being employed to design analogs with reduced off-target effects while maintaining high affinity for their intended biological targets.

In conclusion, 4-(3'-Fluorobenzyloxy)phenylboronic Acid (CAS: 1072951-98-4) continues to demonstrate significant potential across multiple areas of chemical biology and pharmaceutical research. Its unique combination of chemical reactivity and biological activity makes it a valuable tool for drug discovery, diagnostic development, and materials science. As research in this area progresses, we anticipate the emergence of new applications and optimized derivatives that will further expand the utility of this versatile compound in addressing unmet medical needs.

• 779331-47-4(2-(Benzyloxy)-5-fluorophenylboronic Acid)
• 850589-56-9(3-Benzyloxy-5-fluorophenylboronic acid)
• 871126-24-8(2-(3'-Fluorobenzyloxy)phenylboronic acid)
• 1072952-03-4(3-(4'-Fluorobenzyloxy)phenylboronic Acid)
• 1072951-78-0((4-((2-Fluorobenzyl)oxy)phenyl)boronic acid)
• 870779-01-4(2-(4'-Fluorobenzyloxy)phenylboronic acid)
• 848779-87-3(2-(Benzyloxy)-4-fluorophenylboronic Acid)
• 1072951-62-2((3-((3-Fluorobenzyl)oxy)phenyl)boronic acid)
• 871125-82-5((4-((4-Fluorobenzyl)oxy)phenyl)boronic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)